Detalles de la búsqueda
1.
Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.
Blood
; 2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38635762
2.
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas.
Br J Haematol
; 204(1): 151-159, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37690811
3.
Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
Cancer
; 129(2): 255-263, 2023 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36385707
4.
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
Haematologica
; 107(5): 1153-1162, 2022 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34289655
5.
Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery.
Biol Blood Marrow Transplant
; 26(6): 1071-1076, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32088364
6.
Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma.
Haematologica
; 106(1): 255-258, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32079691
7.
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study.
Leukemia
; 38(5): 1107-1114, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38459167
8.
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial.
Blood Adv
; 7(19): 5996-6004, 2023 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37450382
9.
Pregnancy in ß-thalassemia intermedia at two tertiary care centers in Lebanon and Italy: A follow-up report on fetal and maternal outcomes.
Am J Hematol
; 92(6): E96-E99, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28247418
10.
Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma.
Clin Cancer Res
; 28(15): 3378-3386, 2022 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35583610
11.
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.
Transplant Cell Ther
; 28(10): 669-676, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35850429
12.
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Nat Med
; 28(4): 713-723, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35288695
13.
The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant.
Bone Marrow Transplant
; 56(11): 2749-2754, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34253878
14.
The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy.
Transplant Cell Ther
; 27(3): 233-240, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33781518
15.
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells.
Blood Adv
; 5(17): 3397-3406, 2021 09 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34432870
16.
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma.
Blood Cancer J
; 10(8): 79, 2020 08 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32759935
17.
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality.
Blood Adv
; 4(13): 3024-3033, 2020 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32614964
18.
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management.
Blood Adv
; 4(4): 676-686, 2020 02 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-32084260
19.
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.
Blood Adv
; 4(19): 4669-4678, 2020 10 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33002134
20.
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.
Blood Adv
; 4(15): 3776-3787, 2020 08 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32780846